TY - JOUR
T1 - NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models
AU - Iyaswamy, Ashok
AU - Krishnamoorthi, Senthil Kumar
AU - Song, Ju Xian
AU - Yang, Chuan Bin
AU - Kaliyamoorthy, Venkatapathy
AU - Zhang, Huan
AU - Sreenivasmurthy, Sravan G.
AU - Malampati, Sandeep
AU - Wang, Zi Ying
AU - Zhu, Zhou
AU - Tong, Benjamin Chun Kit
AU - Cheung, King Ho
AU - Lu, Jia Hong
AU - Durairajan, Siva Sundara Kumar
AU - Li, Min
N1 - Funding Information:
This study was supported by the grants of ITS/253/14, HMRF-12132061 HMRF-13144471 and HMRF-15163481. We thank the financial support of Innovation and Technology Fund and Health Medical Research Fund from Hong Kong Government.
Publisher copyright:
© 2019 Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC.
PY - 2020/1
Y1 - 2020/1
N2 - Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β (Aβ) and hyper-phosphorylated tau accumulation are accountable for the progressive neuronal loss and cognitive impairments usually observed in AD. Currently, medications for AD offer moderate symptomatic relief but fail to cure the disease; hence development of effective and safe drugs is urgently needed for AD treatment. In this study, we investigated a Chinese medicine (CM) formulation named NeuroDefend (ND), for reducing amyloid β (Aβ) and tau pathology in transgenic AD mice models. Regular oral administration of ND improved cognitive function and memory in 3XTg-AD and 5XFAD mice. In addition, ND reduced beta-amyloid precursor protein (APP), APP C-terminal fragments (CTF-β/α), Aβ and 4G8 positive Aβ burden in 3XTg-AD and 5XFAD mice. Furthermore, ND efficiently reduced the levels of insoluble phospho-tau protein aggregates and AT8 positive phospho tau neuron load in 3XTg-AD mice. Hence, ND could be a promising candidate for the treatment of AD in humans.
AB - Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β (Aβ) and hyper-phosphorylated tau accumulation are accountable for the progressive neuronal loss and cognitive impairments usually observed in AD. Currently, medications for AD offer moderate symptomatic relief but fail to cure the disease; hence development of effective and safe drugs is urgently needed for AD treatment. In this study, we investigated a Chinese medicine (CM) formulation named NeuroDefend (ND), for reducing amyloid β (Aβ) and tau pathology in transgenic AD mice models. Regular oral administration of ND improved cognitive function and memory in 3XTg-AD and 5XFAD mice. In addition, ND reduced beta-amyloid precursor protein (APP), APP C-terminal fragments (CTF-β/α), Aβ and 4G8 positive Aβ burden in 3XTg-AD and 5XFAD mice. Furthermore, ND efficiently reduced the levels of insoluble phospho-tau protein aggregates and AT8 positive phospho tau neuron load in 3XTg-AD mice. Hence, ND could be a promising candidate for the treatment of AD in humans.
KW - Alzheimer's disease
KW - Aβ-plaque
KW - Chinese medicine
KW - NeuroDefend
KW - Neurofibrillary tangles
UR - http://www.scopus.com/inward/record.url?scp=85073756360&partnerID=8YFLogxK
U2 - 10.1016/j.jfda.2019.09.004
DO - 10.1016/j.jfda.2019.09.004
M3 - Journal article
C2 - 31883601
AN - SCOPUS:85073756360
SN - 1021-9498
VL - 28
SP - 132
EP - 146
JO - Journal of Food and Drug Analysis
JF - Journal of Food and Drug Analysis
IS - 1
ER -